Scarica l'app Stockscreener
3.25
14.44%
0.41
Precedente Chiudi:
$2.84
Aprire:
$2.96
Volume 24 ore:
1.03M
Relative Volume:
2.75
Capitalizzazione di mercato:
$114.99M
Reddito:
-
Utile/perdita netta:
$-197.68M
Rapporto P/E:
-0.8644
EPS:
-3.76
Flusso di cassa netto:
$-158.88M
1 W Prestazione:
+49.08%
1M Prestazione:
-0.91%
6M Prestazione:
-11.44%
1 anno Prestazione:
-3.27%
Intervallo 1D:
$2.84
$3.31
Intervallo di 1 settimana:
$2.15
$3.31
Portata 52W:
$1.92
$11.60
Kodiak Sciences Inc Stock (KOD) Company Profile
Nome
Kodiak Sciences Inc
Settore
Industria
Telefono
650-281-0850
Indirizzo
1200 PAGE MILL RD, PALO ALTO, CA
Confronta KOD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KOD
Kodiak Sciences Inc
|
3.25 | 114.99M | 0 | -197.68M | -158.88M | -3.76 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Kodiak Sciences Inc Stock (KOD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-09-05 | Iniziato | H.C. Wainwright | Neutral |
| 2023-12-11 | Ripresa | Goldman | Sell |
| 2023-11-17 | Aggiornamento | CapitalOne | Equal Weight → Overweight |
| 2023-07-27 | Downgrade | UBS | Buy → Neutral |
| 2023-07-25 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2023-07-25 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-07-24 | Downgrade | CapitalOne | Overweight → Equal Weight |
| 2023-07-24 | Downgrade | Jefferies | Buy → Hold |
| 2022-11-15 | Iniziato | CapitalOne | Overweight |
| 2022-08-02 | Downgrade | Citigroup | Neutral → Sell |
| 2022-02-24 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-02-11 | Iniziato | Goldman | Buy |
| 2022-02-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2021-03-12 | Iniziato | Evercore ISI | Outperform |
| 2021-03-01 | Downgrade | Barclays | Equal Weight → Underweight |
| 2021-02-17 | Downgrade | ROTH Capital | Buy → Neutral |
| 2021-01-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-12-11 | Iniziato | Citigroup | Neutral |
| 2020-11-30 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-11-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-13 | Downgrade | Goldman | Buy → Neutral |
| 2020-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-03 | Iniziato | Goldman | Buy |
| 2020-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-02-06 | Iniziato | SunTrust | Buy |
| 2020-01-08 | Iniziato | ROTH Capital | Buy |
| 2020-01-03 | Iniziato | Jefferies | Buy |
| 2019-12-24 | Iniziato | JP Morgan | Overweight |
| 2019-10-15 | Reiterato | Chardan Capital Markets | Buy |
| 2019-02-20 | Iniziato | Chardan Capital Markets | Buy |
| 2018-10-29 | Iniziato | Barclays | Overweight |
| 2018-10-29 | Iniziato | BofA/Merrill | Buy |
| 2018-10-29 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Kodiak Sciences Inc Borsa (KOD) Ultime notizie
April 2025's Promising Penny Stocks - Yahoo Finance
Age Related Vision Dysfunction Market to Reach New Heights - openPR.com
Age Related Vision Dysfunction Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Kodiak Sciences Inc., Outlook Therapeutics, Eye point Pharmaceuticals - The Globe and Mail
Wet Age-Related Macular Degeneration Therapeutics Market Size - openPR.com
Sei Investments Co. Sells 69,599 Shares of Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Kodiak Sciences stock hits 52-week low at $2.15 - Investing.com India
HC Wainwright Comments on Kodiak Sciences Q2 Earnings - Defense World
HC Wainwright Forecasts Kodiak Sciences Q1 Earnings - Defense World
Down -28.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Kodiak Sciences (KOD) - Yahoo Finance
H.C. Wainwright holds Kodiak Sciences stock at Neutral, $3 target By Investing.com - Investing.com South Africa
H.C. Wainwright holds Kodiak Sciences stock at Neutral, $3 target - Investing.com
Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus - MSN
Charles Schwab Investment Management Inc. Sells 6,758 Shares of Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Kodiak Sciences Advances Retinal Therapies with Promising Pipeline - TipRanks
Kodiak Sciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
KODIAK SCIENCES Earnings Results: $KOD Reports Quarterly Earnings - Nasdaq
Kodiak Sciences Cuts Losses by 26%, Advances Two Phase 3 Trials with $168M War Chest - Stock Titan
Is Kodiak Sciences Inc. (KOD) The Hot Biotech Stock Under $5? - Insider Monkey
Bank of New York Mellon Corp Purchases 4,927 Shares of Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Diabetic Macular Edema Pipeline 2025: Therapies Under - openPR
Kodiak Sciences Inc expected to post a loss of 88 cents a shareEarnings Preview - TradingView
Critical Contrast: Metagenomi (NASDAQ:MGX) & Kodiak Sciences (NASDAQ:KOD) - Defense World
10 Hot Biotech Stocks Under $5 - Insider Monkey
Retinal Vein Occlusion Clinical and Non-Clinical Studies, Key - openPR
KOD Completes Enrollment in Phase III Study for Eye Disease Candidate - MSN
Diabetic Retinopathy Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Why Palantir (PLTR) Stock Is Up Today - The Globe and Mail
Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy - Marketscreener.com
Kodiak Sciences completes enrollment in GLOW2 Phase 3 trial - TipRanks
KODKodiak Sciences Inc. Latest Stock News & Market Updates - StockTitan
CDC To Study Vaccines and Autism, Despite Much Research Showing No Link - 69News WFMZ-TV
Clinical Trial Success: Kodiak Enrolls 250+ Patients for Novel Diabetic Eye Drug - Stock Titan
Diabetic Retinopathy Pipeline 2025: Mechanism of Action, Route - openPR
We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate - Yahoo Finance
Kodiak Sciences’ Anti-VEGF Could Win Nicely On Retinal Disorders (NASDAQ:KOD) - Seeking Alpha
Kodiak Sciences Inc. (NASDAQ:KOD) Sees Large Increase in Short Interest - MarketBeat
Elisa Oyj (OTCMKTS:ELMUF) Short Interest Update - Defense World
Kodiak Sciences Inc. (NASDAQ:KOD) Sees Significant Growth in Short Interest - Defense World
166,843 Shares in Kodiak Sciences Inc. (NASDAQ:KOD) Bought by Peapod Lane Capital LLC - MarketBeat
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
SG Americas Securities LLC Has $209,000 Stock Holdings in Levi Strauss & Co. (NYSE:LEVI) - American Banking and Market News
SG Americas Securities LLC Has $206,000 Stake in Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Diabetic Retinopathy Market on Track for Major Expansion by 2034, According to DelveInsight | Novartis, Kodiak Sciences Inc., Regenxbio, Perfuse Therapeutics, Hoffmann-La Roche, Boehringer Ingelheim - Barchart
Diabetic Retinopathy Market on Track for Major Expansion - openPR
Quarterly Dosing Breakthrough: Kodiak's New Glaucoma Treatment Targets Root Causes - StockTitan
Kodiak Sciences Inc.'s (NASDAQ:KOD) institutional investors lost 23% over the past week but have profited from longer-term gains - Simply Wall St
Kodiak Sciences Inc Azioni (KOD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.15%
4.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):